Drug combinations key in treating neurodegenerative diseases

Jan 30, 2009

Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases, Medical College of Georgia researchers say.

Drugs that protect neurons, for example, can be used with those targeting memory to make real progress in treating diseases such as Alzheimer's, says Dr. Jerry Buccafusco, founding director of the MCG Alzheimer's Research Center.

"We realize that with neurodegenerative diseases there will not be one magic bullet," Dr. Buccafusco says. "Developing new therapeutics will require an attack on many different levels. But, right now, there are no FDA-approved compounds out there that are significantly disease-modifying. We're at the point where we're just getting to that."

His review of trends in pharmacological research of neurodegenerative diseases is the featured article in the January issue of NeuroTherapeutics, the journal of the American Society for Experimental NeuroTherapeutics.

Alzheimer's treatment, for instance, should combine molecules that protect neurons from plaque buildup with approved therapies like cholinesterase inhibitors, which treat cognition and memory loss, Dr. Buccafusco says.

Dr. Buccafusco also cited several novel drug candidates developed at the MCG Alzheimer's Research Center, including two molecules prevent cell death in the brain and improve cognition, reaction time and attention.

"What we have to do now is look at drugs that have already been developed to address very specific disease targets and come up with new ways to combine constituent groups of active molecules into a single therapeutic agent," Dr. Buccafusco says. "Drugs should target more than one particular molecular structure and molecular receptor in the central nervous system. The technology is available to design molecules that have multiple properties all in one package. This approach could represent a new frontier for pharmacology."

Advantages to multi-functional drug compounds, he says, include fewer side effects.

Source: Medical College of Georgia

Explore further: Experimental Ebola drug heals all monkeys in study (Update)

add to favorites email to friend print save as pdf

Related Stories

Some anti-inflammatory drugs affect more than their targets

Aug 21, 2014

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved ...

Chemists uncover powerful new click chemistry reactivity

Aug 14, 2014

Chemists led by Nobel laureate K. Barry Sharpless at The Scripps Research Institute (TSRI) have used his click chemistry to uncover unprecedented, powerful reactivity for making new drugs, diagnostics, plastics, smart materials ...

Watching molecules 'dance' in real time

Aug 13, 2014

(Phys.org) —A new technique which traps light at the nanoscale to enable real-time monitoring of individual molecules bending and flexing may aid in our understanding of how changes within a cell can lead ...

Recommended for you

Ebola in mind, US colleges screen some students

15 hours ago

University students from West Africa may be subject to extra health checks when they arrive to study in the United States as administrators try to insulate their campuses from the worst Ebola outbreak in ...

WHO: More Ebola cases in past week than any other

16 hours ago

The past week has seen the highest increase of Ebola cases since the outbreak in West Africa began, the World Health Organization said Friday, offering more evidence that the crisis is worsening.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
not rated yet Feb 01, 2009
This is great but one has to remember what was not said and the real driving force behind this work: "Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases... and extending the earning power of a variety of older drugs for big pharma.